aluates Reports

$ 0.0

Automative

Global Monoclonal antibodies (mAbs) Biosimilars Market Research Report 2025

Published Date: September 2025

Report Code: QYRE-Auto-11D6323

Global Monoclonal antibodies mAbs Biosimilars Market Insights and Forecast to 2028

BUY CHAPTERS

Global Monoclonal antibodies (mAbs) Biosimilars Market Research Report 2025

Code: QYRE-Auto-11D6323

Report

September 2025

Pages:79

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Biocon Ltd.

Celltrion

Dr. Reddy’s Laboratories

Hospira

3SBio Inc

Accord Healthcare

AET BioTech

Allergan plc

Amega Biotech

Monoclonal antibodies (mAbs) Biosimilars Market Size

The global market for Monoclonal antibodies (mAbs) Biosimilars was valued at US$ 4814 million in the year 2024 and is projected to reach a revised size of US$ 5493 million by 2031, growing at a CAGR of 1.9% during the forecast period.

Monoclonal antibodies (mAbs) Biosimilars Market

A biosimilar medicine is a medicinal product of biological origin that is produced in a living organism following a procedure equivalent to a biological drug and adhering to the same quality criteria, hence the name biosimilars. In short, they are biological drugs that are “equivalent” in terms of quality, efficacy and safety to an innovative reference medicinal product.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Monoclonal antibodies (mAbs) Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Monoclonal antibodies (mAbs) Biosimilars.

The Monoclonal antibodies (mAbs) Biosimilars market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Monoclonal antibodies (mAbs) Biosimilars market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Monoclonal antibodies (mAbs) Biosimilars companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Monoclonal antibodies (mAbs) Biosimilars Market Report

Report Metric	Details
Report Name	Monoclonal antibodies (mAbs) Biosimilars Market
Accounted market size in year	US$ 4814 million
Forecasted market size in 2031	US$ 5493 million
CAGR	1.9%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Erythropoietin (EPO) Human Growth Hormone (HGH) Granulocyte- Colony Stimulating Factor (G-CSF) Monoclonal Antibody (mAb) Insulin Interferon (IFN) Others
Segment by Application	Anti-Cancer Anti-Inflammatory/Autoimmune
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Biocon, Celltrion, Dr. Reddy's Laboratories, Hospira, 3SBio, Accord Healthcare, AET Biotech, Allergan, Amega Biotech
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Monoclonal antibodies (mAbs) Biosimilars company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Monoclonal antibodies (mAbs) Biosimilars Market growing?

Ans: The Monoclonal antibodies (mAbs) Biosimilars Market witnessing a CAGR of 1.9% during the forecast period 2025-2031.

What is the Monoclonal antibodies (mAbs) Biosimilars Market size in 2031?

Ans: The Monoclonal antibodies (mAbs) Biosimilars Market size in 2031 will be US$ 5493 million.

Who are the main players in the Monoclonal antibodies (mAbs) Biosimilars Market report?

Ans: The main players in the Monoclonal antibodies (mAbs) Biosimilars Market are Biocon, Celltrion, Dr. Reddy's Laboratories, Hospira, 3SBio, Accord Healthcare, AET Biotech, Allergan, Amega Biotech

What are the Application segmentation covered in the Monoclonal antibodies (mAbs) Biosimilars Market report?

Ans: The Applications covered in the Monoclonal antibodies (mAbs) Biosimilars Market report are Anti-Cancer, Anti-Inflammatory/Autoimmune

What are the Type segmentation covered in the Monoclonal antibodies (mAbs) Biosimilars Market report?

Ans: The Types covered in the Monoclonal antibodies (mAbs) Biosimilars Market report are Erythropoietin (EPO), Human Growth Hormone (HGH), Granulocyte- Colony Stimulating Factor (G-CSF), Monoclonal Antibody (mAb), Insulin, Interferon (IFN), Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Erythropoietin (EPO)

1.2.3 Human Growth Hormone (HGH)

1.2.4 Granulocyte- Colony Stimulating Factor (G-CSF)

1.2.5 Monoclonal Antibody (mAb)

1.2.6 Insulin

1.2.7 Interferon (IFN)

1.2.8 Others

1.3 Market by Application

1.3.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Anti-Cancer

1.3.3 Anti-Inflammatory/Autoimmune

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Perspective (2020-2031)

2.2 Global Monoclonal antibodies (mAbs) Biosimilars Growth Trends by Region

2.2.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Monoclonal antibodies (mAbs) Biosimilars Historic Market Size by Region (2020-2025)

2.2.3 Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Region (2026-2031)

2.3 Monoclonal antibodies (mAbs) Biosimilars Market Dynamics

2.3.1 Monoclonal antibodies (mAbs) Biosimilars Industry Trends

2.3.2 Monoclonal antibodies (mAbs) Biosimilars Market Drivers

2.3.3 Monoclonal antibodies (mAbs) Biosimilars Market Challenges

2.3.4 Monoclonal antibodies (mAbs) Biosimilars Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Monoclonal antibodies (mAbs) Biosimilars Players by Revenue

3.1.1 Global Top Monoclonal antibodies (mAbs) Biosimilars Players by Revenue (2020-2025)

3.1.2 Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Players (2020-2025)

3.2 Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Monoclonal antibodies (mAbs) Biosimilars Revenue

3.4 Global Monoclonal antibodies (mAbs) Biosimilars Market Concentration Ratio

3.4.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Monoclonal antibodies (mAbs) Biosimilars Revenue in 2024

3.5 Global Key Players of Monoclonal antibodies (mAbs) Biosimilars Head office and Area Served

3.6 Global Key Players of Monoclonal antibodies (mAbs) Biosimilars, Product and Application

3.7 Global Key Players of Monoclonal antibodies (mAbs) Biosimilars, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Monoclonal antibodies (mAbs) Biosimilars Breakdown Data by Type

4.1 Global Monoclonal antibodies (mAbs) Biosimilars Historic Market Size by Type (2020-2025)

4.2 Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Type (2026-2031)

5 Monoclonal antibodies (mAbs) Biosimilars Breakdown Data by Application

5.1 Global Monoclonal antibodies (mAbs) Biosimilars Historic Market Size by Application (2020-2025)

5.2 Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Monoclonal antibodies (mAbs) Biosimilars Market Size (2020-2031)

6.2 North America Monoclonal antibodies (mAbs) Biosimilars Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2020-2025)

6.4 North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size (2020-2031)

7.2 Europe Monoclonal antibodies (mAbs) Biosimilars Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2020-2025)

7.4 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size (2020-2031)

8.2 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size by Region (2020-2025)

8.4 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size (2020-2031)

9.2 Latin America Monoclonal antibodies (mAbs) Biosimilars Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2020-2025)

9.4 Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size (2020-2031)

10.2 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2020-2025)

10.4 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Biocon

11.1.1 Biocon Company Details

11.1.2 Biocon Business Overview

11.1.3 Biocon Monoclonal antibodies (mAbs) Biosimilars Introduction

11.1.4 Biocon Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2020-2025)

11.1.5 Biocon Recent Development

11.2 Celltrion

11.2.1 Celltrion Company Details

11.2.2 Celltrion Business Overview

11.2.3 Celltrion Monoclonal antibodies (mAbs) Biosimilars Introduction

11.2.4 Celltrion Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2020-2025)

11.2.5 Celltrion Recent Development

11.3 Dr. Reddy's Laboratories

11.3.1 Dr. Reddy's Laboratories Company Details

11.3.2 Dr. Reddy's Laboratories Business Overview

11.3.3 Dr. Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Introduction

11.3.4 Dr. Reddy's Laboratories Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2020-2025)

11.3.5 Dr. Reddy's Laboratories Recent Development

11.4 Hospira

11.4.1 Hospira Company Details

11.4.2 Hospira Business Overview

11.4.3 Hospira Monoclonal antibodies (mAbs) Biosimilars Introduction

11.4.4 Hospira Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2020-2025)

11.4.5 Hospira Recent Development

11.5 3SBio

11.5.1 3SBio Company Details

11.5.2 3SBio Business Overview

11.5.3 3SBio Monoclonal antibodies (mAbs) Biosimilars Introduction

11.5.4 3SBio Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2020-2025)

11.5.5 3SBio Recent Development

11.6 Accord Healthcare

11.6.1 Accord Healthcare Company Details

11.6.2 Accord Healthcare Business Overview

11.6.3 Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Introduction

11.6.4 Accord Healthcare Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2020-2025)

11.6.5 Accord Healthcare Recent Development

11.7 AET Biotech

11.7.1 AET Biotech Company Details

11.7.2 AET Biotech Business Overview

11.7.3 AET Biotech Monoclonal antibodies (mAbs) Biosimilars Introduction

11.7.4 AET Biotech Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2020-2025)

11.7.5 AET Biotech Recent Development

11.8 Allergan

11.8.1 Allergan Company Details

11.8.2 Allergan Business Overview

11.8.3 Allergan Monoclonal antibodies (mAbs) Biosimilars Introduction

11.8.4 Allergan Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2020-2025)

11.8.5 Allergan Recent Development

11.9 Amega Biotech

11.9.1 Amega Biotech Company Details

11.9.2 Amega Biotech Business Overview

11.9.3 Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Introduction

11.9.4 Amega Biotech Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2020-2025)

11.9.5 Amega Biotech Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Biocon Ltd.

Celltrion

Dr. Reddy’s Laboratories

Hospira

3SBio Inc

Accord Healthcare

AET BioTech

Allergan plc

Amega Biotech

List of Tables

Table 1. Global Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Erythropoietin (EPO)

Table 3. Key Players of Human Growth Hormone (HGH)

Table 4. Key Players of Granulocyte- Colony Stimulating Factor (G-CSF)

Table 5. Key Players of Monoclonal Antibody (mAb)

Table 6. Key Players of Insulin

Table 7. Key Players of Interferon (IFN)

Table 8. Key Players of Others

Table 9. Global Monoclonal antibodies (mAbs) Biosimilars Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 10. Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 11. Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Region (2020-2025) & (US$ Million)

Table 12. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Region (2020-2025)

Table 13. Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 14. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Region (2026-2031)

Table 15. Monoclonal antibodies (mAbs) Biosimilars Market Trends

Table 16. Monoclonal antibodies (mAbs) Biosimilars Market Drivers

Table 17. Monoclonal antibodies (mAbs) Biosimilars Market Challenges

Table 18. Monoclonal antibodies (mAbs) Biosimilars Market Restraints

Table 19. Global Monoclonal antibodies (mAbs) Biosimilars Revenue by Players (2020-2025) & (US$ Million)

Table 20. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Players (2020-2025)

Table 21. Global Top Monoclonal antibodies (mAbs) Biosimilars Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Monoclonal antibodies (mAbs) Biosimilars as of 2024)

Table 22. Ranking of Global Top Monoclonal antibodies (mAbs) Biosimilars Companies by Revenue (US$ Million) in 2024

Table 23. Global 5 Largest Players Market Share by Monoclonal antibodies (mAbs) Biosimilars Revenue (CR5 and HHI) & (2020-2025)

Table 24. Global Key Players of Monoclonal antibodies (mAbs) Biosimilars, Headquarters and Area Served

Table 25. Global Key Players of Monoclonal antibodies (mAbs) Biosimilars, Product and Application

Table 26. Global Key Players of Monoclonal antibodies (mAbs) Biosimilars, Date of Enter into This Industry

Table 27. Mergers & Acquisitions, Expansion Plans

Table 28. Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2020-2025) & (US$ Million)

Table 29. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Type (2020-2025)

Table 30. Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 31. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Type (2026-2031)

Table 32. Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2020-2025) & (US$ Million)

Table 33. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Application (2020-2025)

Table 34. Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 35. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Application (2026-2031)

Table 36. North America Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 37. North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2020-2025) & (US$ Million)

Table 38. North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2026-2031) & (US$ Million)

Table 39. Europe Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 40. Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2020-2025) & (US$ Million)

Table 41. Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2026-2031) & (US$ Million)

Table 42. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 43. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size by Region (2020-2025) & (US$ Million)

Table 44. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size by Region (2026-2031) & (US$ Million)

Table 45. Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 46. Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2020-2025) & (US$ Million)

Table 47. Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2026-2031) & (US$ Million)

Table 48. Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 49. Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2020-2025) & (US$ Million)

Table 50. Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2026-2031) & (US$ Million)

Table 51. Biocon Company Details

Table 52. Biocon Business Overview

Table 53. Biocon Monoclonal antibodies (mAbs) Biosimilars Product

Table 54. Biocon Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2020-2025) & (US$ Million)

Table 55. Biocon Recent Development

Table 56. Celltrion Company Details

Table 57. Celltrion Business Overview

Table 58. Celltrion Monoclonal antibodies (mAbs) Biosimilars Product

Table 59. Celltrion Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2020-2025) & (US$ Million)

Table 60. Celltrion Recent Development

Table 61. Dr. Reddy's Laboratories Company Details

Table 62. Dr. Reddy's Laboratories Business Overview

Table 63. Dr. Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Product

Table 64. Dr. Reddy's Laboratories Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2020-2025) & (US$ Million)

Table 65. Dr. Reddy's Laboratories Recent Development

Table 66. Hospira Company Details

Table 67. Hospira Business Overview

Table 68. Hospira Monoclonal antibodies (mAbs) Biosimilars Product

Table 69. Hospira Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2020-2025) & (US$ Million)

Table 70. Hospira Recent Development

Table 71. 3SBio Company Details

Table 72. 3SBio Business Overview

Table 73. 3SBio Monoclonal antibodies (mAbs) Biosimilars Product

Table 74. 3SBio Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2020-2025) & (US$ Million)

Table 75. 3SBio Recent Development

Table 76. Accord Healthcare Company Details

Table 77. Accord Healthcare Business Overview

Table 78. Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Product

Table 79. Accord Healthcare Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2020-2025) & (US$ Million)

Table 80. Accord Healthcare Recent Development

Table 81. AET Biotech Company Details

Table 82. AET Biotech Business Overview

Table 83. AET Biotech Monoclonal antibodies (mAbs) Biosimilars Product

Table 84. AET Biotech Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2020-2025) & (US$ Million)

Table 85. AET Biotech Recent Development

Table 86. Allergan Company Details

Table 87. Allergan Business Overview

Table 88. Allergan Monoclonal antibodies (mAbs) Biosimilars Product

Table 89. Allergan Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2020-2025) & (US$ Million)

Table 90. Allergan Recent Development

Table 91. Amega Biotech Company Details

Table 92. Amega Biotech Business Overview

Table 93. Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Product

Table 94. Amega Biotech Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2020-2025) & (US$ Million)

Table 95. Amega Biotech Recent Development

Table 96. Research Programs/Design for This Report

Table 97. Key Data Information from Secondary Sources

Table 98. Key Data Information from Primary Sources

Table 99. Authors List of This Report

List of Figures

Figure 1. Monoclonal antibodies (mAbs) Biosimilars Picture

Figure 2. Global Monoclonal antibodies (mAbs) Biosimilars Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Type: 2024 VS 2031

Figure 4. Erythropoietin (EPO) Features

Figure 5. Human Growth Hormone (HGH) Features

Figure 6. Granulocyte- Colony Stimulating Factor (G-CSF) Features

Figure 7. Monoclonal Antibody (mAb) Features

Figure 8. Insulin Features

Figure 9. Interferon (IFN) Features

Figure 10. Others Features

Figure 11. Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2020-2031) & (US$ Million)

Figure 12. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Application: 2024 VS 2031

Figure 13. Anti-Cancer Case Studies

Figure 14. Anti-Inflammatory/Autoimmune Case Studies

Figure 15. Monoclonal antibodies (mAbs) Biosimilars Report Years Considered

Figure 16. Global Monoclonal antibodies (mAbs) Biosimilars Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 17. Global Monoclonal antibodies (mAbs) Biosimilars Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 18. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Region: 2024 VS 2031

Figure 19. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Players in 2024

Figure 20. Global Top Monoclonal antibodies (mAbs) Biosimilars Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Monoclonal antibodies (mAbs) Biosimilars as of 2024)

Figure 21. The Top 10 and 5 Players Market Share by Monoclonal antibodies (mAbs) Biosimilars Revenue in 2024

Figure 22. North America Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. North America Monoclonal antibodies (mAbs) Biosimilars Market Share by Country (2020-2031)

Figure 24. United States Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Canada Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. Europe Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Europe Monoclonal antibodies (mAbs) Biosimilars Market Share by Country (2020-2031)

Figure 28. Germany Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. France Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. U.K. Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Italy Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Russia Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Nordic Countries Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Share by Region (2020-2031)

Figure 36. China Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Japan Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. South Korea Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Southeast Asia Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. India Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Australia Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Latin America Monoclonal antibodies (mAbs) Biosimilars Market Share by Country (2020-2031)

Figure 44. Mexico Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Brazil Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Share by Country (2020-2031)

Figure 48. Turkey Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. Saudi Arabia Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 50. UAE Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 51. Biocon Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2020-2025)

Figure 52. Celltrion Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2020-2025)

Figure 53. Dr. Reddy's Laboratories Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2020-2025)

Figure 54. Hospira Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2020-2025)

Figure 55. 3SBio Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2020-2025)

Figure 56. Accord Healthcare Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2020-2025)

Figure 57. AET Biotech Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2020-2025)

Figure 58. Allergan Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2020-2025)

Figure 59. Amega Biotech Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2020-2025)

Figure 60. Bottom-up and Top-down Approaches for This Report

Figure 61. Data Triangulation

Figure 62. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Biologics and Biosimilars Market Research Report 2025

Global Innovations in Biologics and Biosimilars Market Research Report 2024

Global Generic vs Innovator Drugs Market Research Report 2024

Monoclonal Antibody Biologics and Biosimilars Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Interchangeable Biosimilars Market Research Report 2024

Global Rituximab Biosimilars Market Research Report 2025

Global Tocilizumab Biosimilars Market Research Report 2024

Biosimilar Insulin Market

Global Osteoporosis Biosimilars Market Research Report 2025

Biosimilar of Remicade Market

Innovative Biologics and Biosimilars Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Interchangeable Biological Products Market Research Report 2024

Global Psoriasis Biosimilar Market Research Report 2024

Adalimumab Monoclonal Antibody Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Pharma and Healthcare Social Media Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-14Y6812

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Food Additives Testing Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-34O3983

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Gabapentin API Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-9V17601

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Electronic Informed Consent Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-22C17047

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions